Indegene has announced the acquisition of 100% equity shares in Trilogy Writing & Consulting Inc. through its subsidiaries Indegene, Inc. (USA) and Trilogy Writing and Consulting GmbH. The acquisition was finalized on December 31, 2025. Trilogy Writing & Consulting Inc. will become a wholly-owned subsidiary of Indegene, Inc.
Acquisition Overview
Indegene, through its wholly-owned subsidiaries Indegene, Inc. (USA) and Trilogy Writing and Consulting GmbH, has successfully acquired 100% equity shares in Trilogy Writing & Consulting Inc. The Share Purchase Agreement (SPA) was signed on December 31, 2025.
Details of the Acquired Entity
The acquired entity, Trilogy Writing & Consulting Inc. (formerly known as Trilogy Writing and Consulting ULC (Canada)), specializes in medical writing and is based in Canada. Following the acquisition, Trilogy Writing & Consulting Inc. will transition from being a subsidiary of Trilogy Writing and Consulting GmbH to a wholly-owned subsidiary of Indegene, Inc.
Financial Details
The cost of acquisition is EUR 329,014.00. Trilogy Canada reported a turnover of CAD 892,361.00 in its last financial year.
Trilogy Canada’s Turnover History
Key financial figures for Trilogy Canada’s turnover in recent years:
- 1 Jan 2022 – 31 Dec 2022: CAD 369,636.00
- 1 Jan 2023 – 31 Dec 2023: CAD 505,628.00
- 1 Jan 2024 – 31 Dec 2024: CAD 892,361.00
Strategic Rationale
The acquisition is part of an internal restructuring process. The transaction is considered a related party transaction and was carried out on an arm’s length basis.
Source: BSE
